Table 1.
Study | Type of Study | Technique | Number of Patients | Inclusion Dates | Mean Size of Lesions (cm) | Median Follow Up (Months) | LTC | LTP at 1 Year | LTP at 3 Years | Median OS (Months) | OS at 1 Year | OS at 3 Years | OS at 5 Years |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
T.D. Yan (2007) [30] | Retrospective | RFA | 55 | - | 2.1 +/− 1.1 | 24 | 62% | - | - | 33 | 85% | 46% | - |
K. Yamakado (2009) [36] | Retrospective | RFA | 78 | 2002–2008 | 2.0 +/− 1.0 | 24 | 86% | 10% | 21% | 38 | 84% | 56% | 35% |
T.C. Chua (2010) [37] | Retrospective | RFA | 100 | 2000–2010 | - | 23 | - | - | - | 36 | 87% | 50% | 30% |
A. Gillams (2013) [38] | Retrospective | RFA | 122 | 2002–2011 | 1.7 (0.5–4) | 12 | - | - | - | 41 | - | 57% | - |
T. de Baere (2015) [25] | Retrospective | RFA | 566 (293 mCCR) | 2002–2010 | 1.7 +/− 0.9 | 36 | 92% | 10% | 18% | 62 | 93% | 76% | 56% |
J. Ferguson (2015) [31] | Retrospective | RFA | 157 | 2000–2013 | 1.6 +/− 0.6 | 28 | 88% | - | - | 33 | 89% | 44% | 20% |
Y. Matsui (2015) [39] | Retrospective | RFA | 84 | 2001–2012 | 1.5 +/− 0.7 | 38 | 86% | 12% | 18% | 67 | 95% | 65% | 52% |
I. Kurilova (2018) [32] | Retrospective | MWA | 50 | 2011–2016 | 1.0 (0.3–3.2) | 26 | 90% | 7% | 14% | 59 | 94% | 82% | 61% |
M. Fonck (2018) [27] | Retrospective | RFA, MWA, CA | 209 | 2002–2013 | 1.0 (0.2–4.6) | 50 | - | - | - | 68 | 95% | - | 55% |
J. Zhong (2019) [40] | Retrospective | RFA | 70 | 2008–2014 | 1.4 +/− 0.6 | 46 | 90% | 3% | 10% | 52 | 97% | 75% | 44% |
M.R. Callstrom (2020) [26] | Prospective | CA | 128 (63 mCCR) | 2014–2016 | 1.0 +/− 0.6 | 91% | 9% | 16% | - | 98% | - | - | |
T. Hasegawa (2020) [23] | Prospective | RFA | 70 | 2008–2014 | 1.0 +/− 0.5 | 57 | 91% | - | 9% | - | - | 84% | - |
RFA: radiofrequency, MWA: microwave, LTC: local tumor control, LTP: local tumor progression, OS: overall survival, mCCR: lung metastases of colorectal cancer, CA: cryoablation.